Patients with poorly differentiated tumors, advanced stages, or lymphatic metastasis exhibited significantly lower DACH1 expression and higher DNMT1 expression, underscoring the potential of aberrant expression of DACH1 and DNMT1 as molecular biomarkers for the early diagnosis and prognostic evaluation of CRC. The gene discussed is DNMT1; the disease is colorectal carcinoma.